References
- Maloney D G, Grillo-Lopez A J, White C A, Bodkin D, Schilder R J, Neidhart J A, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188–2195
- Venugopal P, Sivaraman S, Huang X K, Nayini J, Gregory S A, Preisler H D. Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk Res 2000; 24: 411–415
- Voso M T, Pantel G, Rutella S, Weis M, D'Alò F, Urbano R, et al. Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica 2002; 87: 918–925
- Liu N S, Grimm E, Poindexter N, Rodriguez M A, Hagemeister F B, Pro B, et al. Antibody dependent cellular cytotoxicity and natural killer cell activity in patients with recurrent indolent lymphoma receiving rituximab in combination with GM-CSF. Blood 2003; 102: 411a
- Huhn D, von Schilling C, Wilhelm M, Ho A D, Hallek M, Kuse R, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 98: 1326–1331
- Itala M, Geisler C H, Kimby E, Juvonen E, Tjonnfjord G, Karlsson K, et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol 2002; 69: 129–134
- Hainsworth J D, Litchy S, Barton J H, Houston G A, Hermann R C, Bradof J E, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003; 21: 1746–1751
- O'Brien S M, Kantarjian H, Thomas D A, Giles F J, Freireich E J, Cortes J, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 2165–2170
- Byrd J C, Murphy T, Howard R S, Lucas M S, Goodrich A, Park K, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19: 2153–2164